Celladon Mydicar drug receives FDA fast track status Pharmaceutical Business Review Celladon's investigational product candidate, Mydicar, has been granted fast track designation by the US Food and Drug Administration (FDA), used to treat patients with advanced heart failure. Mydicar is a genetically targeted enzyme replacement ... Celladon Corporation Receives FDA Fast Track Designation for Its ... |
